Open access · CC-BY
via OpenAlex
Macular Atrophy in Neovascular Age-Related Macular Degeneration
Mark C. Gillies, Alex P. Hunyor, Jennifer Arnold, Robyn H. Guymer, Sebastián Wolf, Francois L. Pecheur, Marion Ronit Munk, Ian L. McAllister
Ophthalmology · 2019 · ▲ 98 citations
Abstract
PURPOSE: To investigate differences in the development of macular atrophy (MA) over 24 months between treat-and-extend (T&E) ranibizumab and aflibercept in patients with neovascular age-related macular degeneration (nAMD). DESIGN: A phase 4 randomized, partially masked, multicenter study. PARTICIPANTS: Individuals 50 years of age or older diagnosed with active, treatment-naïve subfoveal choroidal neovascularization secondary to nAMD with baseline best-corrected visual acuity (BCVA) of 23 logarithm of minimum angle of resolution letters or more. METHODS: Patients were randomized 1:1 to receive either intravitreal injections of ranibizumab 0.5 mg or aflibercept 2.0 mg and were treated according to the same reading center-guided T&E regimen after 3 initial monthly injections. MAIN OUTCOME MEASURES: The primary outcome was mean change in square root area of MA from baseline to month 24. Key secondary outcomes included number of injections and mean change in BCVA from baseline to months 12 and 24. RESULTS: Two hundred seventy-eight patients were included in the analysis (ranibizumab 0.5 mg, n = 141; aflibercept 2.0 mg, n = 137). Mean change in square root area of MA from baseline to month 24 was +0.36 mm (95% confidence interval [CI], 0.27-0.45 mm) for ranibizumab and +0.28 mm (95% CI, 0.19-0.37 mm) for aflibercept (treatment difference, +0.08 mm [95% CI, -0.05 to 0.21 mm]; P = 0.24). The proportion of patients with MA increased from 7% (10/141) to 37% (43/117) for ranibizumab and from 6% (8/137) to 32% (35/108) for aflibercept from baseline to month 24. The average number of injections received per year was similar between both groups: 9.6 (95% CI, 9.2-10.0) for ranibizumab and 9.5 (95% CI, 9.1-9.9) for aflibercept. The mean change in BCVA from baseline to month 24 was +6.6 letters (95% CI,4.7-8.5 letters) for the ranibizumab group and +4.6 letters (95% CI, 2.7-6.6 letters) for the aflibercept group ( P = 0.15). Rates of adverse events (AEs) were similar between both groups. CONCLUSIONS: No significant differences in the rate of development or growth of MA over 24 months were observed between ranibizumab and aflibercept in nAMD patients treated using an identical T&E regimen.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.ophtha.2019.08.023
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Gillies, M.C., Hunyor, A.P., Arnold, J., Guymer, R.H., Wolf, S., Pecheur, F.L., Munk, M.R., & McAllister, I.L. (2019). Macular Atrophy in Neovascular Age-Related Macular Degeneration. <em>Ophthalmology</em>. https://doi.org/10.1016/j.ophtha.2019.08.023
Vancouver
Gillies MC, Hunyor AP, Arnold J, Guymer RH, Wolf S, Pecheur FL, et al. Macular Atrophy in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2019. doi:10.1016/j.ophtha.2019.08.023.
BibTeX
@article{mark2019Macula,
title = {Macular Atrophy in Neovascular Age-Related Macular Degeneration},
author = {Mark C. Gillies and Alex P. Hunyor and Jennifer Arnold and Robyn H. Guymer and Sebastián Wolf and Francois L. Pecheur and Marion Ronit Munk and Ian L. McAllister},
journal = {Ophthalmology},
year = {2019},
doi = {10.1016/j.ophtha.2019.08.023},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Vastra Gotaland Region 2020
Open access · US-GOV
The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration
International journal of ophthalmology 2026
Citation only
Efficacy and safety of intravitreal conbercept treat-and-extend regimens in neovascular age-related macular degeneration.
New England Journal of Medicine 2006
Open access · OA
Ranibizumab for Neovascular Age-Related Macular Degeneration
Archives of Ophthalmology 1999
Open access · OA
Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin
Retina 2006
Citation only
INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION
IRCCS San Raffaele 2011
Open access · US-GOV